[18 F]-Fluoro-2-deoxy-D-galactose positron emission tomography/computed tomography as complementary imaging tool in patients with hepatocellular carcinoma.
Kirstine P Bak-FredslundSusanne KeidingGerda Elisabeth VilladsenStine KramerSven SchlanderMichael SørensenPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
For the detection of extrahepatic HCC metastases, 18 F-FDGal PET/CT was superior both to standard clinical work-up with contrast-enhanced CT, and/or MRI, and to 18 F-FDG PET/CT in patients deemed suitable for locoregional treatment. 18 F-FDGal PET/CT led to a change in the planned treatment in 10% of the patients whereas 18 F-FDG PET/CT did not change the planned treatment in any patient.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- contrast enhanced
- end stage renal disease
- magnetic resonance imaging
- ejection fraction
- chronic kidney disease
- diffusion weighted
- newly diagnosed
- dual energy
- peritoneal dialysis
- pet imaging
- image quality
- diffusion weighted imaging
- prognostic factors
- case report
- quantum dots
- photodynamic therapy